Koers Pathfinder Cell Therapy, Inc. Other OTC
Aandelen
PFND
US70319A1060
Biotechnologie & Medisch Onderzoek
Omzet 2013 | 0,05 0,05 | Omzet 2014 | - | Marktkapitalisatie | 534K 492K |
---|---|---|---|---|---|
Nettowinst (verlies) 2013 | -1 mln. -922K | Nettowinst (verlies) 2014 | -1 mln. -922K | EV/omzet 2013 | 246.023.185 x |
Nettoschuld 2013 | 3,94 mln. 3,64 mln. | Nettoschuld 2014 | 4,96 mln. 4,57 mln. | EV/omzet 2014 | - |
K/w-verhouding 2013 |
-5,48
x | K/w-verhouding 2014 |
-0,38
x | Werknemers | - |
Dividendrendement 2013 * |
-
| Dividendrendement 2014 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Rick Franklin
CEO | Chief Executive Officer | 78 | 02-09-11 |
John Benson
DFI | Director of Finance/CFO | 62 | 02-09-11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Rick Franklin
CEO | Chief Executive Officer | 78 | 02-09-11 |
John Benson
DFI | Director of Finance/CFO | 62 | 02-09-11 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+43,36% | 54,64 mld. | |
-5,31% | 39,92 mld. | |
+37,52% | 38,82 mld. | |
+14,75% | 26,86 mld. | |
-12,56% | 26,22 mld. | |
-22,45% | 18,78 mld. | |
+0,04% | 12,16 mld. | |
+25,12% | 12,21 mld. | |
+26,04% | 11,94 mld. |